Metraipolis › archive › dc_dce22019e1c5
Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenic POLE mutation: a case report — Europe PMC PMID:42491054
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42491054
- DOI
- 10.1007/s13691-[numero omesso]-x
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T07:21:34.913Z
- SHA-256 of the archived text
1ee025ee903d0569138e64207aa35b339461b06b64972b63f63b322a3c13965e- Stable URL of this page
https://metraipolis.com/documento/dc_dce22019e1c5
How to cite
Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenic POLE mutation: a case report — Europe PMC PMID:42491054 — Europe PMC (en), https://europepmc.org/article/MED/42491054 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dce22019e1c5 (Metraipolis archive dc_dce22019e1c5, sha256 1ee025ee903d0569138e64207aa35b339461b06b64972b63f63b322a3c13965e)
BibTeX
@misc{dcdce22019e1c5,
title = {Clinical implications of immune checkpoint inhibitor in chemotherapy-resistant advanced endometrial cancer with a pathogenic POLE mutation: a case report — Europe PMC PMID:42491054},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42491054},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dce22019e1c5; sha256 1ee025ee903d0569138e64207aa35b339461b06b64972b63f63b322a3c13965e},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42491054. Agents can read the archived copy with the MCP tool read_document.